Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2013 Dec;33(12):5495-500.

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

Author information

1
KU Leuven, Laboratory of Pediatric Immunology, Onderwijs & Navorsing 1, Herestraat 49 bus 811, 3000 Leuven, Belgium. an.coosemans@gmail.com.

Abstract

AIM:

Treatment options are limited in uterine cancer, leading to a poor prognosis. Overexpression of Wilms' tumor gene 1 (WT1), the highest ranked tumor antigen, is attractive for immunotherapy.

PATIENTS AND METHODS:

Six pre-treated patients with uterine cancer received four weekly vaccines of autologous dendritic cells (DCs) electroporated with WT1 mRNA. Safety, feasibility and immunogenicity were assessed. In cases of response, patients received monthly booster vaccines.

RESULTS:

The technique was feasible. One patient had a local allergic reaction. Three out of four Human Leucocyte Antigen-A2 (HLA-A2)-positive patients showed an oncological response; an enrichment of WT1-specific T-cells was observed in two of them. Two HLA-A2-negative patients did not show an oncological or an immunological response.

CONCLUSION:

A first series of six patients with uterine cancer treated with WT1 mRNA-electroporated DCs is presented herein. Oncological and immunological responses were observed and are supportive for further research.

KEYWORDS:

DC immunotherapy; WT1; endometrial carcinoma; uterine cancer; uterine sarcoma

PMID:
24324087
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center